Las Vegas, NV -- (SBWIRE) -- 12/16/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: OCZ Technology Group Inc. (NASDAQ:OCZ), Metabolix, Inc. (NASDAQ:MBLX), Amarin Corporation plc (ADR) (NASDAQ:AMRN), Delcath Systems, Inc. (NASDAQ:DCTH)
OCZ Technology Group Inc. (NASDAQ:OCZ) managed to keep its fall at -5.89% on below -normal volume of 5.76M shares. The stock settled at $0.0735 after floating in a range of $0.07 to $0.09. Its latest price has reached market capitalization of $5.01 million. Its 52-week range has been $0.06 to $2.77. OCZ Technology Group, Inc. designs, manufactures, and distributes solid state drives (SSDs) and computer components primarily in the United States, Germany, the Middle East, Africa, and European countries.
Has OCZ Found The Bottom and Ready To Move Up? Find Out Here
Metabolix, Inc. (NASDAQ:MBLX) traded down on a volume of -4.26 million, lower than its standard daily volume. Shares have dropped-4.26% to $1.35. Over the last twelve months, the stock has lost-22.41% and faced a worst price of $0.75. Metabolix, Inc., a bioscience company, develops and commercializes technologies to produce renewable alternatives to petroleum-based products comprising advanced biopolymers, biobased industrial chemicals, and bioenergy. It produces a family of biopolymers known as polyhydroxyalkanoates (PHAs), which occur naturally in living organisms and are chemically similar to polyesters.
Has MBLX Found The Bottom And Ready To Gain Momentum? Find Out Here
Amarin Corporation plc (ADR) (NASDAQ:AMRN) settled 3.59% higher at $1.73 on below -normal volume of 2.50M shares during the last trading day. The stock has its 12-month high at $9.29 and 52-week low price was $1.36. It traded in a range of $1.63 to $1.79 during the last trading day. Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids.
Why Should Investors Buy AMRN After the Recent Fall? Just Go Here and Find Out
In the last trading session, Delcath Systems, Inc. (NASDAQ:DCTH) was down on high volume, trading at a volume of 2.87M versus its average daily volume of 1.33 million shares. At $0.230, the stock has attained market capitalization of 29.02 million. Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology. The company?s proprietary technology enables the administration of high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. It is primarily involved in the development of CHEMOSAT/Melblez Kit system that administers concentrated regional chemotherapy to the liver.
Why Should Investors Buy DCTH After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)